Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

NCT04886271 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HX009

Sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd.